AIM ImmunoTech Inc. — Director's Dealing 2021

Feb 24, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AIM ImmunoTech Inc. (AIM)
CIK: 0000946644
Period of Report: 2021-02-24

Reporting Person: EQUELS THOMAS K. (Director, CEO & President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-24	Common Stock	P	11062	$2.26	Acquired	209630	Direct